Denali Therapeutics DNLI Earnings Call Transcripts

NASDAQ DNLI
$20.27 -0.06 (-0.30%)
As of: Nov 10, 2026 · 10:25 AM EST
2 earnings calls on file for Denali Therapeutics, from Q2 2026 to Q3 2026. Each transcript opens in a new tab.
Latest earnings call

Denali Therapeutics Q3 2026 Earnings Call

Nov 3, 2026 8,896 words · 39 min read
  • Laura HansenVP, Investor Relations
  • Ryan WattsChief Executive Officer
  • Katie PengChief Commercial Officer
  • Peter ChinChief Medical Officer and Head of Development
Prepared remarks and the full analyst Q&A, speaker by speaker.
Earnings calls

Denali Therapeutics Earnings Call Transcripts

Calls2
LatestNov 3, 2026
SinceQ2 2026

Fiscal 2026

All 2 Denali Therapeutics transcripts Register to get access to Denali Therapeutics’s earnings call transcripts.